Biogen (BIIB) Akcija Cena
Biogen Cena
Ieņēmumi auga par 7,1 % gadā pēdējos 19 gados līdz 9,89 B USD. Peļņa uz akciju auga par 14,9 % gadā pēdējos 19 gados. Biogen neto marža tagad ir 13,1 %, samazinājusies no 14,2 % pirms dažiem gadiem. Analītiķu mērķa cenas mediāna ir 240,00 USD, t. i. zem pašreizējo cenu par 4,0 %. No 44 analītiķiem 32 iesaka pirkt — kopējais konsenss ir Pirkt.
Biogen akcijas cena
Iegūstiet šos datus caur Eulerpool API
100 000 pieprasījumu/mēn. bez maksas · bez kartes
Biogen biznesa modelis un akciju analīze
Bieži uzdotie jautājumi par Biogen akciju
Biogen Inc.'s business model revolves around the development, manufacturing, and commercialization of therapies for neurological, autoimmune, and rare diseases. As a leading biotechnology company, Biogen focuses on creating innovative treatments to address unmet medical needs. With a diverse portfolio encompassing multiple therapeutic areas, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, Biogen strives to improve patients' lives worldwide. Through strategic collaborations and scientific advancements, the company continues to invest in cutting-edge research and development to bring transformative therapies to patients, making Biogen a key player in the biopharmaceutical industry.
Biogen Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Biogen Inc in the market are Amgen Inc, AbbVie Inc, and Gilead Sciences Inc.
Biogen Inc is a renowned biotechnology company with a rich history and impressive background. Founded in 1978, Biogen has consistently aimed to develop innovative therapies for patients facing serious neurological and neurodegenerative diseases. Over the years, the company has made significant contributions to the field of biotechnology, especially in areas like multiple sclerosis (MS) and spinal muscular atrophy (SMA). Biogen's mission involves relentless pursuit of scientific excellence and commitment to improving patients' lives. With a diverse portfolio of groundbreaking therapies and a global presence, Biogen continues to be a leading player in the biotechnology industry, dedicated to transforming the course of human health.
Biogen Inc, a leading biotechnology company, has achieved several significant milestones. Notably, the company successfully introduced the first treatment for multiple sclerosis, revolutionizing the lives of patients worldwide. Biogen also developed ground-breaking therapies for spinal muscular atrophy, empowering patients with this rare genetic disease. Moreover, the company made strides in neurology and introduced medications addressing Alzheimer's disease and Parkinson's disease. Biogen's commitment to innovation has led to these remarkable achievements, positioning the company as a pioneer in the biotech industry. As an influential player, Biogen Inc continues to drive advancements in healthcare, improving the quality of life for countless individuals.
Biogen Inc operates in several countries and regions around the world. As a leading biotechnology company, Biogen Inc has a significant presence in the United States, where it is headquartered. Additionally, Biogen Inc has operations and presence in Europe, including countries such as Germany, France, Italy, and Switzerland. The company also serves markets in Asia, with a presence in Japan, South Korea, and several other countries in the region. Biogen Inc's global footprint allows it to reach a wide range of patients and healthcare providers, ensuring its innovative therapies and treatments are accessible to individuals in various parts of the world.
Biogen Inc is a biotechnology company known for its commitment to scientific innovation and improving patients' lives. Guided by their corporate philosophy, Biogen Inc strives to discover, develop, and deliver innovative therapies for neurological, autoimmune, and rare diseases. The company values integrity, diversity, and inclusion in their pursuit of breakthrough treatments, always putting patients at the forefront. Biogen Inc's collaborative approach, dedication to scientific rigor, and passion for making a difference have earned it a leading position in the biotech industry. With a focus on transformative therapies, Biogen Inc continues to drive advancements in healthcare and empower patients worldwide.
Analītiķi pašlaik nosaka vidējo Biogen akcijas mērķa cenu 238,69 USD (mediāna: 240,00 USD), kas ir -4,5 % pret pēdējo cenu. Konsenss balstās uz 44 analītiķu vērtējumiem.
44 analītiķi pašlaik vērtē Biogen akciju: 32 iesaka pirkt, 11 turēt un 1 pārdot. 2026. gadam analītiķi sagaida, ka Biogen gūs 10,55 B USD ieņēmumus un 12,45 USD peļņu uz akciju.
Pēc pašreizējā kursa Biogen akcija maksā 223,21 EUR (249,88 USD).
Biogen akcija (BIIB) tiek kotēta 11 biržās, tostarp: NASDAQ (BIIB), London (0R1B.L), SIX (Zürich) (BIIB.SW), XETRA (IDP.DE), Frankfurt (IDP.F), München (IDP.MU), Düsseldorf (IDP.DU), Hamburg (IDP.HM).
Biogen Inc. is a biopharmaceutical company specializing in the research, development, and marketing of therapies for neurological, hematological, and autoimmune diseases. It was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen currently has three main business segments: Neurology, Hematology, and Biosimilars. The Neurology division focuses on the development and marketing of drugs for the treatment of Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and other neurological disorders. The Hematology division focuses on the development of therapies for blood diseases such as Hemophilia and Sickle Cell Anemia. The Biosimilars division focuses on the development of generic versions of biological drugs. Biogen has partnerships with other major companies such as Eisai Co. and Ionis Pharmaceuticals to work on the development of new drugs and therapies. The company's business model is based on the sale of patented drugs and the development of new therapies. In summary, Biogen is a biopharmaceutical company specializing in the development and marketing of therapies for neurological, hematological, and autoimmune diseases, aiming to improve the lives of patients worldwide.
gaidāmā apgrozījums Biogen ir 10,55 B USD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.
gaidāmā peļņa Biogen ir 1,83 B USD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.
Biogen cenas un peļņas rādītājs (P/E) pašlaik ir 20,07. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt Biogen akcijas vērtību.
Biogen cenas un apgrozījuma rādītājs (P/S) pašlaik ir 3,48. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā Biogen akcijas vērtības mērs.
Biogen Eulerpool kvalitātes rādītājs ir 2/10.
Biogen ISIN ir US09062X1037. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.
Biogen WKN ir 789617. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.
Biogen tikeris ir BIIB. Tikeris tiek izmantots Biogen akciju tirdzniecībai biržā.
Biogen akcija
Biogen Salīdzināmo uzņēmumu grupa
Biogen Biržas kods
Biogen FIGI
Visi Biogen fundamentālie rādītāji un padziļinātā analīze
Mūsu akciju analīze par Biogen ietver svarīgus finanšu rādītājus, piemēram, apgrozījumu, peļņu, P/E rādītāju, P/S rādītāju, EBIT, kā arī informāciju par dividendēm. Turklāt mēs aplūkojam aspektus kā akcijas, tirgus kapitalizāciju, parādus, pašu kapitālu un saistības no Biogen. Ja meklējat sīkāku informāciju par šīm tēmām, piedāvājam detalizētas analīzes mūsu apakšlapās: